The Top 5 Biosimilar Articles for the Week of June 20

Here are the top 5 biosimilar articles for the week of June 20, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 20, 2022.

Number 5: The FDA granted a new indication for rheumatoid arthritis for Riabni, a rituximab biosimilar, and Organon and Shanghai Henlius Biotech entered into a licensing agreement for 2 oncology biosimilar candidates.

Number 4: Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.

Number 3: STADA Arzneimittel and Alvotech announced the launch of their high-concentration, citrate-free adalimumab biosimilar (Hukyndra) in France, Germany, Finland, and Sweden, with more European countries to come.

Number 2: Not long after the company announced its new global initiative to promote access and increase adoption of biosimilars, Sandoz’ application for its high-concentration adalimumab biosimilar was accepted by the European Union’s regulatory agency for review.

Number 1: Iceland-based Alvotech announced that the pureplay biosimilars company is debuting on the public market starting June 16.

To read all of these articles and more, visit